Institutional members access full text with Ovid®

Share this article on:

A price for cost-effectiveness: Implications for recombinant human activated protein C (rhAPC)

Chalfin, Donald B. MD, MS, FCCM; Teres, Daniel MD, FCCM; Rapoport, John PhD


Maimonides Medical Center and Albert Einstein School of Medicine

Tufts University School of Medicine

Mount Holyoke College

* See also p. 1.

© 2003 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins